1. Participant has evidence of macular or retinal disorders other than AMD in the study eye(s) such as:
a. Diabetic retinopathy (unless retinopathy is limited to fewer than 10 microaneurysms and/or small retinal hemorrhages).
b. Angioid streaks.
c. Central serous choroidopathy.
d.Surface wrinkling retinopathy (epiretinal membrane) that is more severe than mild surface wrinkling retinpathy.
e. Optic atrophy.
f. Pigmentary abnormalities considered by the Clinical Center ophthalmologist to be less typical of AMD than of some other condition, such as pattern dystrophy or chronic central serous retinopathy.
g. Myopic crescent of the optic disc the width of which is greater than or equal to 50% of the longest diameter of the disc, or pigmentary abnormalities in the posterior pole considered by the clinic ophthalmologist more likely to be due to myopia than to AMD.
h. Macular hole or pseudohole.
i. Retinal vein occlusion, active uveitis, presumed ocular histoplasmosis syndrome, other sight-threatening retinopathies, and other retinal degenerations, significant explained or unexplained visual field loss, or any other type of retinopathy or retinal degeneration.
j. A choroidal nevus within 2 DD of the center of the macula associated wtih depigmentation or overlying atypical drusen.
k. Other ocular diseases or conditions, the presence of which may now or in the future complicate evaluation of AMD.
l. Amblyopia (in study eye only)
2. Participant has known adverse reaction to fluorescein dye and refuses further fluorescein angiograms.
3. Participant is receiving evaluation by an eye care professional more frequently than every 4 months.
4. Non-AREDS2 participant currently enrolled in another study that may likely affect adherence with the ForeseeHome study.
5. Previous retinal or other ocular surgical procedures, the effects of which may now or in the future complicate assessment of the progression of AMD in the study eye. Examples are radial keratotomy, traveculectomy, cryosurgery (except to repair a peripheral retinal hole), lamellar keratoplasty, pterygium surgery that affects or threatens the visual axis, radiation for ocular tumor, or repair of corneal or sclera laceration. Cataract surgery more than one month prior to randomization is not an exclusion criterion unless complicated by a condition that is causing or is likely to cause a decrease in visual acuity. Laser photocoagulation for drusen and non-choroidal neovascularization in the non-study eye will not be exclusion factors.
6. Chronic requirement for any systemic or ocular medication administered for other diseases such as glaucoma and known to be toxic to the retina or optic nerve, such as:
b. Chlroroquine/Hydroxychloroquine (Plaquinil)
f. Chronic systemic steroid use of at least 10 mg per day or more
7. Cataract surgery within one month of randomization